Amoxicillin Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial
ConclusionThe plasma exposure of tegoprazan, M1, 14-hydroxyclarithromycin and bismuth was increased after the coadministration of tegoprazan, clarithromycin, amoxicillin and bismuth. The coadministration exhibited favorable safety and tolerability.Clinical Trials RegistrationCTR20230643. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 13, 2024 Category: Drugs & Pharmacology Source Type: research

A sophisticated virulence repertoire and colistin resistance of Citrobacter freundii ST150 from a patient with sepsis admitted to ICU in a tertiary care hospital in Uganda, East Africa: Insight from genomic and molecular docking analyses
Infect Genet Evol. 2024 Apr 9:105591. doi: 10.1016/j.meegid.2024.105591. Online ahead of print.ABSTRACTSepsis and multidrug resistance comprise a complex of factors attributable to mortality among intensive care unit (ICU) patients globally. Pathogens implicated in sepsis are diverse, and their virulence and drug resistance remain elusive. From a tertiary care hospital ICU in Uganda, we isolated a Citrobacter freundii strain RSM030 from a patient with sepsis and phenotypically tested it against a panel of 16 antibiotics including imipenem levofloxacin, cotrimoxazole and colistin, among others. We sequenced the organism's g...
Source: Infection, Genetics and Evolution - April 11, 2024 Category: Genetics & Stem Cells Authors: Reuben S Maghembe Maximilian A K Magulye Emmanuel Eilu Simon Sekyanzi Abdalah Makaranga Savannah Mwesigwa Eric Katagirya Source Type: research

Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology : WJG - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research